All News
ACR Supports Legislation to Improve Oversight and Transparency of Prior Authorization Use
Rheumatology Leaders Join a Coalition of National Medical Specialties in Urging Congress to Protect Patients from Prior Authorization Requirements in Medicare Advantage Plans
Read Article
RheumNow Podcast – Drug Ad Transparency (6.7.19)
Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.
Read Article
ACR Announces New Executive Vice President Steven Echard
The American College of Rheumatology (ACR) Board of Directors is pleased to announce that Steven C. Echard, IOM, CAE is the new Executive Vice President (EVP) of the American College of Rheumatology.
Read Article
RheumNow Podcast – Rituximab Monitoring (5.31.19)
Dr. Jack Cush presents the news and best of rheumatology and medicine from the past week on RheumNow.com
Read Article
The Cost of Physician Burnout
An article in the Annals of Internal Medicine has analyzed the cost-consequences of physician burnout, including costs related to physician turnover and reduced clinical hours.
Read Article
RheumNow Podcast – Medical Selfies (5.24.19)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read Article
ACR Statement on CMS Medicare Advantage Final Rule
In August 2018, the CMS announced that Medicare Advantage (MA) plans would be allowed to utilize step therapy for Part B drugs. The American College of Rheumatology (ACR) expressed strong concerns about this proposal.
Read Article
RheumNow Podcast – Richer or Poorer (5.17.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
RheumNow Podcast – Periodontitis in RA Relatives (5.10.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
RheumNow Podcast – DESIREABLE Results (5.3.19)
Dr. Jack Cush reviews the latest journal articles and rheumatology news from the past week on RheumNow.com:
Read Article
New ACR/AF Guidelines on JIA Polyarthritis and Uveitis
The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA).
Read Article
RheumNow Podcast – Take it Back Jack! (4.26.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
RheumNow Podcast – Eat Your Veggies (4.19.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Polypharmacy Blunts Responses and Ups the Safety Risks
A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.
Read Article
EULAR 2019 Update to Lupus Management
The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.
Read Article
RheumNow Podcast – A Tofa Two-fer (4.12.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
RheumNow Podcast – Loretta Lynn Arthritis (3.29.19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
RheumNow Podcast – You Owe Me a DEXA (3.15.19)
Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.
Read Article
Brazilian Guidelines for Systemic Autoimmune Myopathies
The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).
Read Article
EULAR Consensus Guidelines for Juvenile Localized Scleroderma
A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).
Read Article
